An interventional study of No SLS toothpaste and Medium SLS toothpaste in Oral Mucosal Disorder, sponsored by Solventum US LLC. Terminated at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Solventum US LLC · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the incidence of oral tissue sloughing through self-report by study subjects and by professional dental examinations.
The primary objective of this study is to evaluate the incidence of oral tissue sloughing through self-report by study subjects and by professional dental examinations. Adverse events will be tracked through study dental examinations and subject diaries with twice daily use of the 3M Oral Rinse used in combination with toothpaste containing one of three levels (no, medium, high) of Sodium Lauryl Sulfate (SLS).
Determine the subjects' acceptance of sloughing and/or other side effects
Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3M Oral Rinse in combination with no SLS toothpaste (A)
Drug: No SLS toothpaste · Device: Anti-plaque
3M Oral Rinse in combination with medium SLS toothpaste (B)
Drug: Medium SLS toothpaste · Device: Anti-plaque
3M Oral Rinse in combination with high SLS toothpaste (C)
Drug: High SLS toothpaste · Device: Anti-plaque
Toothpaste no Sodium Lauryl Sulfate
Also known as: Sensodyne ProNamel Fresh Breath Toothpaste
Less than or equal to X ppm Sodium Lauryl Sulfate
Also known as: Clinpro Tooth Creme
More than or equal to X ppm Sodium Lauryl Sulfate
Also known as: Colgate Cavity Protection Toothpaste
Rinse prevents bacterial adherence to teeth
Also known as: 3M Oral Rinse
Number of Participants With Oral Mucosal Exfoliation (Oral Sloughing)
Percentage of participants who experienced oral sloughing as reported either by the subject or determined by the dental evaluator.
Time frame: End of treatment (3 weeks)
The Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores
Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)
Time frame: Mid-Treatment (10 days)
The Number of Participants With a Given Range of Average Oral Mucosal Sloughing Index Scores.
Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)
Time frame: End of Treatment (3 weeks)
The Number of Participants Reporting Their Acceptance Levels of Side Effects
Subjects were questioned regarding how acceptable were your side effects. Using the following responses of: Completely unacceptable, somewhat unacceptable, somewhat acceptable, completely acceptable, did not experience side effects
Time frame: End of Treatment (3 weeks)
| Milestone | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste |
|---|---|---|---|
| Started | 18 | 18 | 17 |
| Completed | 0 | 0 | 0 |
| Not completed | 18 | 18 | 17 |
| Withdrew: Needed crown & cleaning | 0 | 0 | 1 |
| Withdrew: Study was terminated | 18 | 18 | 16 |
Percentage of participants who experienced oral sloughing as reported either by the subject or determined by the dental evaluator.
| Participants | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste |
|---|---|---|---|
| Number of Participants With Oral Mucosal Exfoliation (Oral Sloughing) | 15 | 14 | 13 |
Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)
| Participants | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste |
|---|---|---|---|
| 0 no sloughing | 8 | 6 | 7 |
| (0.0, 0.5] | 9 | 8 | 6 |
| (0.5, 1.0] | 1 | 3 | 2 |
| (1.0, 1.5] | 0 | 0 | 1 |
| (1.5, 2.0] | 0 | 1 | 0 |
Average score based on the mean of sloughing scores over 12 intra-oral areas. The sloughing score uses a 6 point scale as follows: 0= no sloughing, 1=flecks of desquamation, 2=sheets of desquamation, 3=redness, not due to plaque, 4=erosion of mucosa, 5=ulcerated areas. The twelve intra-oral areas of the mouth are as follows: dorsal and ventral surfaces of the tongue, floor and roof of the mouth, right and left buccal mucosa, gingival tissue. (upper right, upper anterior, upper left, lower left, lower anterior, lower right)
| Participants | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste |
|---|---|---|---|
| 0 No sloughing | 6 | 9 | 7 |
| (0.0, 0.5] | 9 | 6 | 6 |
| (0.5, 1.0] | 3 | 2 | 2 |
| (1.0, 1.5] | 0 | 1 | 1 |
Subjects were questioned regarding how acceptable were your side effects. Using the following responses of: Completely unacceptable, somewhat unacceptable, somewhat acceptable, completely acceptable, did not experience side effects
| Participants | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste |
|---|---|---|---|
| Completely unacceptable | 2 | 1 | 2 |
| Somewhat unacceptable | 2 | 0 | 1 |
| Somewhat acceptable | 1 | 4 | 4 |
| Completely acceptable | 1 | 4 | 3 |
| Did not experience side effects | 12 | 9 | 7 |
Collected over Within 3 weeks of starting treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Comparator: No SLS Toothpaste | 0/18 (0%) | 0/18 (0%) | 15/18 (83.3%) |
| Comparator: Medium SLS Toothpaste | 0/18 (0%) | 0/18 (0%) | 15/18 (83.3%) |
| Comparator: High SLS Toothpaste | 0/17 (0%) | 0/17 (0%) | 16/17 (94.1%) |
| Event | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste |
|---|---|---|---|
| Oral mucosal exfoliationGastrointestinal disorders | 15/18 | 14/18 | 13/17 |
| Dry mouthGastrointestinal disorders | 3/18 | 1/18 | 3/17 |
| Hypoaesthesia oralGastrointestinal disorders | 1/18 | 1/18 | 2/17 |
| DysgeusiaGastrointestinal disorders | 2/18 | 2/18 | 1/17 |
| Mouth injuryGastrointestinal disorders | 0/18 | 2/18 | 1/17 |
| Breath odorGastrointestinal disorders | 0/18 | 0/18 | 1/17 |
| DyspepsiaGastrointestinal disorders | 0/18 | 0/18 | 1/17 |
| GlossitisGastrointestinal disorders | 0/18 | 0/18 | 1/17 |
| Oral discomfortGastrointestinal disorders | 1/18 | 0/18 | 1/17 |
| Sensitivity of teethGastrointestinal disorders | 0/18 | 0/18 | 1/17 |
| Age, Continuous(years) | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste | Total |
|---|---|---|---|---|
| Mean | 43.2 ± 10.3 | 39.7 ± 12.09 | 38.5 ± 11.82 | 40.5 ± 11.38 |
| Sex: Female, Male(Participants) | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste | Total |
|---|---|---|---|---|
| Female | 11 | 11 | 9 | 31 |
| Male | 7 | 7 | 8 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 3 |
| Not Hispanic or Latino | 16 | 18 | 16 | 50 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 18 | 17 | 17 | 52 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste | Total |
|---|---|---|---|---|
| United States | 18 | 18 | 17 | 53 |
| Number of Participants with Oral Tissue Sloughing at Baseline(Participants) | Comparator: No SLS Toothpaste | Comparator: Medium SLS Toothpaste | Comparator: High SLS Toothpaste | Total |
|---|---|---|---|---|
| Count of participants | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Mar 2020, 2 months.
Results were first posted in Nov 2021, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluorophosphate